ESC Clinical Practice Guidelines on Cardio-Oncology:

main point of contact after cancer treatment has been completed and the cancer team will organise follow-ups as required – this may be from every few months to one follow-up appointment a year. Who is at risk of cardiotoxicity after cancer treatment has finished? The risk of long-term effects depends on several factors. People most at risk include those with existing heart-related risk factors (e.g. high blood pressure or diabetes) or existing heart conditions. The type of cancer treatment received also matters, for example, risk is increased with anthracycline chemotherapy, such as doxorubicin, epirubicin, daunorubicin and idarubicin, with chest radiation, and with long-term hormonal treatments, such as those for prostate cancer. Long-term effects may be more likely if you developed a new heart problem during treatment, but this depends on how mild or serious that heart problem is, and whether it required heart medication. Other factors such as lifestyle and environment are also important and any lifestyle- related changes you make will help reduce the risk. What can I do to reduce the risk of late effects? You can reduce your risk of cardiovascular disease by: • Making healthy lifestyle choices (diet, exercise, weight control, smoking cessation) • Working with
